Generics Co. Rips Novartis' Bid To Combine Reclast Suits

Law360, New York (May 1, 2013, 2:02 PM EDT) -- Wockhardt USA LLC told a New Jersey federal judge Tuesday that three patent infringement suits launched by Novartis Pharmaceuticals Corp. seeking to block drugmakers from developing generic versions of its osteoporosis drug Reclast and oncology drug Zometa should be tried separately.

Wockhardt urged U.S. Magistrate Judge Madeline C. Arleo to reject Novartis' April 12 motion to consolidate the three suits against Wockhardt, Sun Pharmaceutical Industries Ltd., Actavis LLC and Accord Healthcare Inc., saying the cases were at completely different stages of litigation and the alleged overlap...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.